PMID- 33322093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201229
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 12
DP  - 2020 Dec 13
TI  - Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by 
      Reperfusion Therapies.
LID - 10.3390/jcm9124028 [doi]
LID - 4028
AB  - Establishing a prognosis at hospital admission after stroke is a major challenge. 
      Inflammatory processes, hemostasis, vascular injury, and tissue remodeling are 
      all involved in the early response to stroke. This study analyzes whether 22 
      selected biomarkers, sampled at admission, predict clinical outcomes in 153 
      stroke patients treated by thrombolysis and mechanical endovascular treatment 
      (MET). Biomarkers were related to hemostasis (u-plasminogen activator/urokinase 
      (uPA/urokinase), serpin E1/PAI-1, serpin C1/antithrombin-III, kallikrein 
      6/neurosin, alpha 2-macroglobulin), inflammation[myloperoxidase (MPO), chemokine 
      ligand 2/monocyte chemoattractant protein-1 chemokine (CCL2/MCP-1), adiponectin, 
      resistin, cell-free DNA (cDNA), CD40 Ligand (CD40L)], endothelium activation 
      (Vascular cell adhesion protein 1 (VCAM-1) intercellular adhesion molecule 1 
      (ICAM-1), platelet endothelial cell adhesion molecule 1 (CD31/PECAM-1)], and 
      tissue remodeling (total cathepsin S, osteopontin, cystatin C, neuropilin-1, 
      matrix metallopeptidase 2 (MMP-2), matrix metallopeptidase 3 (MMP-3), matrix 
      metallopeptidase 9 (MMP-9), matrix metallopeptidase 13 (MMP-13)]. Correlations 
      between their levels and excellent neurological improvement (ENI) at 24 h and 
      good outcomes (mRS 0-2) at three months were tested. Osteopontin and favorable 
      outcomes reached the significance level (p = 0.008); the adjusted OR per SD 
      increase in log-transformed osteopontin was 0.34 (95%CI, 0.18-0.62). The 
      relationship between total cathepsin S and MPO with ENI, was borderline of 
      significance (p = 0.064); the adjusted OR per SD increase in log-transformed of 
      total cathepsin S and MPO was 0.54 (95%CI, 0.35-0.81) and 0.51 (95%CI, 
      0.32-0.80), respectively. In conclusion, osteopontin levels predicted three-month 
      favorable outcomes, supporting the use of this biomarker as a complement of 
      clinical and radiological parameters for predicting stroke prognosis.
FAU - Meseguer, Elena
AU  - Meseguer E
AUID- ORCID: 0000-0002-7184-2614
AD  - Department of Neurology and Stroke Center, APHP Bichat Hospital, F-75018 Paris, 
      France.
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Diallo, Devy
AU  - Diallo D
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Labreuche, Julien
AU  - Labreuche J
AD  - Department of Biostatistics Universite de Lille, CHU Lille, ULR 2694-METRICS: 
      Evaluation des Technologies de Sante et des Pratiques Medicales, F-59000 Lille, 
      France.
FAU - Charles, Hugo
AU  - Charles H
AD  - Department of Neurology and Stroke Center, APHP Bichat Hospital, F-75018 Paris, 
      France.
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Delbosc, Sandrine
AU  - Delbosc S
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Mangin, Gabrielle
AU  - Mangin G
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Monteiro Tavares, Linsay
AU  - Monteiro Tavares L
AD  - Department of Neurology and Stroke Center, APHP Bichat Hospital, F-75018 Paris, 
      France.
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Caligiuri, Giuseppina
AU  - Caligiuri G
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Nicoletti, Antonino
AU  - Nicoletti A
AUID- ORCID: 0000-0002-2623-0897
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
FAU - Amarenco, Pierre
AU  - Amarenco P
AD  - Department of Neurology and Stroke Center, APHP Bichat Hospital, F-75018 Paris, 
      France.
AD  - LVTS, Inserm U1148, Universite de Paris, F-75018 Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20201213
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7763291
OTO - NOTNLM
OT  - acute stroke
OT  - assessment
OT  - biomarkers
OT  - outcomes
OT  - thrombectomy
OT  - thrombolytic therapy
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
PMCR- 2020/12/13
CRDT- 2020/12/16 01:02
PHST- 2020/11/24 00:00 [received]
PHST- 2020/12/04 00:00 [revised]
PHST- 2020/12/09 00:00 [accepted]
PHST- 2020/12/16 01:02 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
PHST- 2020/12/13 00:00 [pmc-release]
AID - jcm9124028 [pii]
AID - jcm-09-04028 [pii]
AID - 10.3390/jcm9124028 [doi]
PST - epublish
SO  - J Clin Med. 2020 Dec 13;9(12):4028. doi: 10.3390/jcm9124028.